Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Removing the clock gene BMAL1 makes bacteria-engulfing defence cells in the body more effective, a new study from the Radcliffe Department of Medicine has found.

This is the first time a clock gene has been found to affect resistance to bacterial pneumonia, a fatal disease responsible for 5% of all deaths in the UK each year. (The main image depicts a a computer-generated image of a group of Gram-positive, Streptococcus pneumoniae bacteria, one of the bacteria types that cause the disease. Image credit: CDC PHIL). 

Most living things have an internal body clock which regulates when they sleep and when they wake up. A complex set of genes turning on and off, make this body clock run over roughly 24 hours, and a gene known by the acronym BMAL1 is one of the master regulators of this clock, controlling many other body clock genes and pathways.

Read more (Radcliffe Department of Medicine)

This research is also featured in a The Conversation article.

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.